Vertex continues to enroll and dose the MAD portion of the Phase 1/2 clinical study for VX-670 in people with myotonic dystrophy type 1, in which the safety and efficacy of VX-670 will be evaluated.

Vertex continues to enroll and dose the MAD portion of the Phase 1/2 clinical study for VX-670 in people with myotonic dystrophy type 1, in which the safety and efficacy of VX-670 will be evaluated.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a prominent player in the biotechnology industry with a market capitalization of $123.2 billion, finds itself at a critical juncture as it ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a prominent player in the biotechnology industry with a market capitalization of $123.2 billion, finds itself at a critical juncture as it navigates ...

The increase was primarily a result of the approximately $100 million registered direct offering completed in June of 2024 and the receipt of the $75 million payment for the clinical advancement ...

Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. For more information about Entrada, please visit our website, www.entradatx.com and follow us on ...